Cullinan Therapeutics financials
$15.35+0.79%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $18.9M |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $18.9M |
| Gross margin | — | — | — | — | 100.0% |
| Operating income | -$241.6M | -$196.9M | -$191.1M | -$132.1M | -$68.0M |
| Net income | -$198.2M | -$149.4M | -$133.4M | $111.2M | -$65.6M |
| Net margin | — | — | — | — | −346.1% |
| Diluted EPS | $-3.36 | $-2.78 | $-3.21 | $2.38 | $-1.52 |
| EBITDA | -$241.3M | -$196.6M | -$190.3M | -$130.8M | -$64.8M |
| Operating cash flow | -$175.8M | -$145.3M | -$134.3M | -$126.7M | -$43.4M |
| Free cash flow | -$175.8M | -$145.3M | -$134.5M | -$127.8M | -$43.4M |
| Diluted shares | 59.1M | 53.8M | 41.6M | 46.6M | 43.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $88.3M | $83.0M | $98.4M | $156.2M | $59.8M |
| Short-term investments | $289.6M | $316.0M | $368.6M | $311.1M | $230.7M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $448.4M | $621.8M | $484.2M | $561.1M | $437.2M |
| Total liabilities | $39.6M | $31.5M | $30.3M | $26.1M | $11.8M |
| Shareholders' equity | $408.7M | $590.3M | $453.9M | $535.0M | $425.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology